SWEDEN; UNITED KINGDOM —SenzaGen has completed the purchase of all equity in Alcyomics, integrating the United Kingdom-based enterprise into its corporate group. The transaction involved an initial cash payment of approximately GBP 2.12 million, supported by existing corporate funds and a directed convertible bond issue of SEK 25 million to Eiffel Investment Group. Additional conditional earn-out provisions capped at approximately GBP 1.88 million, remain linked to future performance metrics.
Alcyomics specializes in preclinical immunotoxicology assessments centered on biological pharmaceuticals, operating primarily out of Newcastle. During the 2025 and 2026 financial cycle, the target enterprise registered revenues around SEK 19.5 million accompanied by an EBITDA margin of approximately 24 percent. Sedermera Corporate Finance managed advisory duties for the transaction, with legal counsel provided by Vinge and Freeths.
This corporate integration expands analytical capabilities within the biological therapeutics sector, specifically addressing regulatory and market shifts favoring animal-free testing methods. By absorbing specialized preclinical platforms, the acquiring entity strengthens its commercial positioning across advanced drug development segments where demand for human-relevant safety data continues to rise.
The transaction highlights ongoing consolidation trends within the life sciences sector, as enterprises seek proprietary laboratory technologies to meet evolving compliance standards. Stakeholders across biotechnology and pharmaceutical research face increasing pressure to adopt ethical, non-animal methodologies, making specialized providers targets for strategic expansion and portfolio diversification.
SenzaGen operates as a specialized enterprise focused on chemical safety testing solutions utilizing genomics and machine learning frameworks for regulatory decision support. Alcyomics is a specialized provider of non-animal immunotoxicology and safety solutions tailored for biological drug development applications.
